<DOC>
	<DOCNO>NCT00697476</DOCNO>
	<brief_summary>The purpose study evaluate maximum tolerate dose , activity safety profile combination vorinostat topotecan patient recurrent small cell lung cancer</brief_summary>
	<brief_title>Study Oral Vorinostat Combination With Topotecan Patients With Chemosensitive Recurrent SCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Histologically cytologically proven diagnosis SCLC ; Limited extensivestage disease patient receive single chemotherapy regimen combine modality ( chemotherapy + chest radiotherapy ) regimen relapse completion firstline chemotherapy ( sensitive relapse ) ; Age &gt; /= 18 year ; ECOG Performance Status 02 ; Life expectancy least 12 week ; Measurable lesion accord RECIST criterion ; Adequate cardiac , hepatic , renal , bone marrow function ; Written inform consent . Prior treatment HDAC inhibitor ; Symptomatic and/or unstable preexist brain metastasis ; Superior Vena Cava Syndrome ; Spinal cord compression ; Severe uncontrolled medical disease ( Hypertension , diabetes , congestive heart failure , myocardial infarction within 6 month study , chronic renal disease , active uncontrolled infection ) ; Other coexist malignancy malignancy diagnose within last 5 year exception basal cell carcinoma cervical cancer situ ; Pregnant breastfeed woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>second line chemotherapy</keyword>
</DOC>